Back to results
US 10,744,183 B2Granted
Methods of using ZSCAN4 for rejuvenating human cells
AssigneeElixirgen Therapeutics, Inc.
InventorMinoru S. H. Ko
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeElixirgen Therapeutics, Inc.
InventorMinoru S. H. Ko
Estimating the term…
The present disclosure relates to methods for increasing telomere length in one or more human adult cells and/or increasing genome stability of one or more human adult cells, for example by contacting one or more human adult cells with an agent that increases expression of Zscan4 in the one or more human adult cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a telomere abnormality, of rejuvenating one or more human adult cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human adult cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 is also provided.
A method of increasing telomere length in one or more human bone marrow cells or blood cells isolated from a human subject suffering from a telomere disorder with bone marrow failure, comprising introducing in vitro into the one or more human bone marrow cells or blood cells an isolated nucleic acid molecule encoding human Zscan4 wherein introduction of the isolated nucleic acid molecule encoding human Zscan4 induces telomere lengthening in the one or more human bone marrow cells or blood cells as compared to human bone marrow cells or blood cells that are not contacted with the isolated nucleic acid, and wherein the isolated nucleic acid molecule is comprised in a synthetic mRNA or a Sendai virus vector.
A method of engrafting bone marrow cells or blood cells in a human subject suffering from Fanconi anemia or dyskeratosis congenita, comprising:
Dependencies are inferred from the claim text.